FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking - Abbott Laboratories (N
The FDA approved Abbott's Libre Duo 10 Day, the first wearable device to monitor both glucose and ketones continuously. The system, for diabetes patients aged 2+, received De Novo approval after clinical trials. Abbott plans integrations with insulin pumps from Beta Bionics, Sequel Med Tech, Insulet, Tandem Diabetes, and Medtronic by 2027. ABT shares rose 0.32% to $116.30. Analysts note potential competition with DexCom.
How this was made
The 30-second read
Why it matters
The approval creates a new product category, may boost Abbott's sales in diabetes care, and could shift market dynamics against rivals.
Market read
A first‑of‑its‑kind FDA approval that could drive Abbott's growth and influence the broader diabetes device market.
What to watch
Potential supply‑chain constraints and competition from emerging continuous ketone sensors.
Background
Abbott Laboratories received FDA De Novo clearance for its Libre Duo 10‑Day sensor, a novel wearable that continuously measures both glucose and ketone levels for diabetes patients.
Ticker impact
FDA approval of Abbott's Libre Duo 10‑Day Continuous Dual Glucose Ketone Monitoring System, the first wearable to track ketones continuously.
Potential short‑term upside as investors price in the product launch and partnership pipeline.
Regulatory clearance is a material catalyst; the device addresses an unmet need and may drive sales growth and market share gains.
Market effects
Strengthens the diabetes device sector and could pressure competitors like DexCom.
U.S. market sees new FDA‑cleared product, boosting healthcare innovation perception.
First global dual‑monitor may expand Abbott's international footprint in diabetes care.
Counterpoint
Adoption could be slower than expected if reimbursement or integration with pumps faces hurdles.
Key entities
- CompanyAbbott Laboratories
Manufacturer of the newly approved Libre Duo 10‑Day sensor.
- RegulatorU.S. Food and Drug Administration
Agency that granted the De Novo clearance for the device.
